AR069085A1 - Anticuerpos especificos de los peptidos beta- amiloides y sus usos como agentes de diagnostico o drogas - Google Patents

Anticuerpos especificos de los peptidos beta- amiloides y sus usos como agentes de diagnostico o drogas

Info

Publication number
AR069085A1
AR069085A1 ARP080104708A ARP080104708A AR069085A1 AR 069085 A1 AR069085 A1 AR 069085A1 AR P080104708 A ARP080104708 A AR P080104708A AR P080104708 A ARP080104708 A AR P080104708A AR 069085 A1 AR069085 A1 AR 069085A1
Authority
AR
Argentina
Prior art keywords
mammal
antibody
abeta8
level
peptides
Prior art date
Application number
ARP080104708A
Other languages
English (en)
Spanish (es)
Inventor
Eugeen Vanmechelen
Andre Delacourte
Pierre Gronet
Veronique Blanchard-Bregeon
Luc Bluee
Marie Gompel
Nicolas Sergeant
Laurent Pradier
Original Assignee
Sanofi Aventis
Inst Nat Sante Rech Med
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis, Inst Nat Sante Rech Med, Innogenetics Nv filed Critical Sanofi Aventis
Publication of AR069085A1 publication Critical patent/AR069085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP080104708A 2007-10-29 2008-10-28 Anticuerpos especificos de los peptidos beta- amiloides y sus usos como agentes de diagnostico o drogas AR069085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119537 2007-10-29

Publications (1)

Publication Number Publication Date
AR069085A1 true AR069085A1 (es) 2009-12-30

Family

ID=38925731

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104708A AR069085A1 (es) 2007-10-29 2008-10-28 Anticuerpos especificos de los peptidos beta- amiloides y sus usos como agentes de diagnostico o drogas

Country Status (27)

Country Link
US (1) US8343493B2 (de)
EP (1) EP2205633A1 (de)
JP (1) JP5421277B2 (de)
KR (1) KR20100097651A (de)
CN (1) CN101883792B (de)
AP (1) AP2957A (de)
AR (1) AR069085A1 (de)
AU (1) AU2008317705B2 (de)
CA (1) CA2703825A1 (de)
CL (1) CL2008003197A1 (de)
CO (1) CO6270369A2 (de)
CR (1) CR11396A (de)
EA (1) EA201070539A1 (de)
EC (1) ECSP10010142A (de)
HN (1) HN2010000880A (de)
IL (1) IL205398A0 (de)
MA (1) MA31793B1 (de)
MX (1) MX2010004660A (de)
MY (1) MY155144A (de)
NI (1) NI201000075A (de)
NZ (1) NZ585000A (de)
TN (1) TN2010000197A1 (de)
TW (1) TW200936605A (de)
UA (1) UA103602C2 (de)
UY (1) UY31433A1 (de)
WO (1) WO2009056490A1 (de)
ZA (1) ZA201002989B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4275747A2 (de) 2016-07-19 2023-11-15 Duke University Therapeutische anwendungen von cpf1-basierter genomeditierung

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
AU2008203703C1 (en) * 2007-01-05 2014-04-03 University Of Zurich Method of providing disease-specific binding molecules and targets
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
PE20130527A1 (es) 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
EP2511296A1 (de) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
EP3269736B1 (de) 2012-05-10 2019-11-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Konformationsspezifische antikörper gegen amyloid (beta)-oligomere
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP7448174B2 (ja) * 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
JP2019533426A (ja) 2016-07-18 2019-11-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
JOP20200041A1 (ar) 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
EP4448564A1 (de) * 2021-12-17 2024-10-23 F. Hoffmann-La Roche AG Neuer antikörper zum nachweis von amyloid beta 42 (a-beta42)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4275747A2 (de) 2016-07-19 2023-11-15 Duke University Therapeutische anwendungen von cpf1-basierter genomeditierung

Also Published As

Publication number Publication date
ZA201002989B (en) 2011-07-27
NZ585000A (en) 2012-08-31
UA103602C2 (ru) 2013-11-11
TN2010000197A1 (en) 2011-11-11
AU2008317705A1 (en) 2009-05-07
CN101883792A (zh) 2010-11-10
AP2957A (en) 2014-08-31
UY31433A1 (es) 2009-05-29
IL205398A0 (en) 2010-12-30
CR11396A (es) 2012-10-18
JP2011502139A (ja) 2011-01-20
US8343493B2 (en) 2013-01-01
ECSP10010142A (es) 2010-07-30
JP5421277B2 (ja) 2014-02-19
CO6270369A2 (es) 2011-04-20
US20110059092A1 (en) 2011-03-10
EP2205633A1 (de) 2010-07-14
CA2703825A1 (en) 2009-05-07
CL2008003197A1 (es) 2010-01-15
KR20100097651A (ko) 2010-09-03
WO2009056490A1 (en) 2009-05-07
MA31793B1 (fr) 2010-10-01
HN2010000880A (es) 2014-03-10
TW200936605A (en) 2009-09-01
CN101883792B (zh) 2014-08-27
AU2008317705B2 (en) 2014-06-05
MX2010004660A (es) 2010-07-30
AP2010005249A0 (en) 2010-06-30
NI201000075A (es) 2010-09-23
MY155144A (en) 2015-09-15
EA201070539A1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
AR069085A1 (es) Anticuerpos especificos de los peptidos beta- amiloides y sus usos como agentes de diagnostico o drogas
Smith et al. Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy
Iaccarino et al. Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
CO6231037A2 (es) Anticuerpos anti-hepcidina y usos de los mismos
Oda et al. Localization of nephritis-associated plasmin receptor in acute poststreptococcal glomerulonephritis
Li et al. BAR domain-containing FAM92 proteins interact with Chibby1 to facilitate ciliogenesis
BRPI0410261B8 (pt) anticorpo monoclonal que se liga especificamente ao probnp, métodos para detecção específica de probnp in vitro e para diagnóstico de insuficiência cardíaca in vitro, kit para medição de probnp, e linhagem celular de hibridoma mab 1.21.3
Caronti et al. Anti-β2-glycoprotein I antibodies bind to central nervous system
BR0310088A (pt) Pré-direcionamento de droga por meio de anticorpos biespecìficos e constructos haptênicos compreendendo um veìculo peptìdico e o(s) agente(s) ativo(s)
AR085198A1 (es) Composicion farmaceutica
ATE497508T1 (de) Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
TW201305201A (zh) 測定澱粉樣肽之抗體、套組及方法
CO6230998A2 (es) Un metodo para aislar una molecula de enlace especifico dericado de desordenes asociados a proteinas, moleculas de enlace especificas y objetivos
JP6307509B2 (ja) 腎機能の診断若しくは監視又は腎機能障害の診断方法
FR2933773B1 (fr) Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
Rasmussen et al. A novel antihuman C3d monoclonal antibody with specificity to the C3d complement split product
CN110678757B (zh) 诊断或监测肾功能或诊断肾功能障碍的方法
Cabral et al. Membrane-associated aquaporin-1 facilitates osmotically driven water flux across the basolateral membrane of the thick ascending limb
AU2015343202A1 (en) PIF binding as a marker for immune dysregulation
ES2846836T3 (es) Método para predecir la sensibilidad a una terapia combinada con lenvatinib y everolimus
Paule et al. Cytoskeletal remodelling proteins identified in fetal-maternal interface in pregnant women and rhesus monkeys
Kovačević et al. Monoclonal antibody 26 cross-reactive with β2-glycoprotein I affects human trophoblast invasion in vitro
US20230013244A1 (en) Pif binding as a marker for immune dysregulation
Zeng et al. Integrin α5 is involved in fibronectin-induced human extravillous trophoblast invasion

Legal Events

Date Code Title Description
FB Suspension of granting procedure